No Data
Revance Therapeutics Ticks Higher as Holder Says Crown Deal Undervalues Company
Key Deals for the Week: Patterson, Hershey & Mondelez, AIG & Nippon and More
Shareholder Alert: Ademi LLP Investigates Whether Revance Therapeutics, Inc. Is Obtaining a Fair Price for Its Public Shareholders
Revance Therapeutics Board Recommends Stockholders Tender Shares to Crown Laboratories
Express News | Crown Laboratories: Tender Offer Is Scheduled to Expire at One Minute After 11:59 P.m., Eastern Time on January 13, 2025
Revance Therapeutics Board of Directors Recommend Stockholders Tender Their Shrs >RVNC